Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133181 | 0.87 | S1PR1 (0.54) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2135592 | 0.82 | S1PR1 (0.53) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2132833 | 0.77 | S1PR1 (0.63) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2719007 | 0.75 | S1PR1 (0.53) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2134348 | 0.74 | S1PR1 (0.56) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2134529 | 0.74 | S1PR1 (0.59) | S1PR1S1PR5S1PR3 | |
| SCHEMBL1420432 | 0.74 | S1PR1 (0.66) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2719004 | 0.72 | S1PR1 (0.61) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2137395 | 0.70 | S1PR1 (0.62) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2137957 | 0.70 | S1PR1 (0.54) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445891-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010148649-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |